Suchergebnisse - "Pinato, David J"

PubPharm (7)

1

Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma : A matching-adjusted indirect comparison

enthalten in: European journal of cancer (Oxford, England : 1990) | 2024

von Agirrezabal, I. | Bouattour, M. | Pinato, D. | +6

2

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy : A global, observational study

enthalten in: Hepatology communications | 2023

von Joerg, V. | Scheiner, B. | D Alessio, A. | +33

3

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

enthalten in: Hepatology international | 2023

von Vithayathil, M. | D'Alessio, A. | Fulgenzi, C. | +32

CommentIn: Hepatol Int. 2023 Aug;17(4):827-829. - PMID 37188999

4

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2022

von Vithayathil, M. | D'Alessio, A. | Fulgenzi, C. | +32

CommentIn: Liver Int. 2022 Nov;42(11):2352-2353. - PMID 36162086

5

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis : A real-world study

enthalten in: Hepatology (Baltimore, Md.) | 2022

von D'Alessio, A. | Fulgenzi, C. | Nishida, N. | +32

CommentIn: Hepatology. 2022 Oct;76(4):906-908. - PMID 35491442

6

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score

enthalten in: Journal of hepatology | 2022

von Scheiner, B. | Pomej, K. | Kirstein, M. | +38

CommentIn: J Hepatol. 2022 Apr;76(4):987-988. - PMID 34780876

7

Shifting paradigms in the systemic management of hepatocellular carcinoma

enthalten in: The lancet. Gastroenterology & hepatology | 2020

von Pinato, D.

1
[1]